Compare INSG & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSG | ICCC |
|---|---|---|
| Founded | 1996 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 88.9M |
| IPO Year | 2000 | 1995 |
| Metric | INSG | ICCC |
|---|---|---|
| Price | $3.01 | $11.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.17 | N/A |
| AVG Volume (30 Days) | ★ 230.9K | 11.9K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.51 |
| Revenue | ★ $313,832,000.00 | $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.21 | N/A |
| P/E Ratio | ★ N/A | $21.94 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $3.30 | $4.67 |
| 52 Week High | $21.90 | $12.10 |
| Indicator | INSG | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 32.52 | 58.16 |
| Support Level | N/A | $9.47 |
| Resistance Level | $4.68 | $11.38 |
| Average True Range (ATR) | 0.40 | 0.48 |
| MACD | -0.14 | 0.09 |
| Stochastic Oscillator | 0.49 | 65.65 |
Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.